We are eXmoor, a leading technical and strategic consultancy specialising in cell and gene therapies (ATMPs) and biopharmaceuticals
Location: United States, Alaska, Susitna North
Employees: 51-200
Total raised: $35M
Founded date: 2004
Investors 1
| Date | Name | Website |
| 17.03.2021 | MVM Partne... | mvm.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.05.2023 | Series A | $35M | MVM Partne... |
Mentions in press and media 5
| Date | Title | Description |
| 30.10.2024 | Virica Biotech is Building an Ecosystem to Ramp Up AAV Production | Portfolio company Virica Biotech made two recent collaboration announcements highlighting the industry embracing their cell enhancing platform for improving adeno-associated vectors (AAVs) production. Virica and eXmoor Pharma announced a ne... |
| 24.09.2024 | Quell Therapeutics Expands Manufacturing Capabilities for CAR-Treg Cell Therapy Pipeline Through Partnership with eXmoor pharma | London, UK and Bristol, UK, 24 September 2024 –Quell Therapeutics Ltd (“Quell” or “the Company”), a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, and eXm... |
| 30.05.2023 | eXmoor pharma Closes USD 35M Series A Funding | eXmoor pharma, a Bristol, UK-based end-to-end cell and gene therapy (CGT) manufacturing partner, raised USD35M in Series A funding. The round saw participation from Kineticos Ventures and existing investor MVM Partners. In conjunction with ... |
| 11.03.2021 | eXmoor bags £12M: Bristol cell and gene therapy startup to build dedicated CGT facility | Bristol-based eXmoor is an expert cell and gene therapy (CGT) services company that has just bagged £12 million in funding from MVM Partners, a specialist healthcare investment firm. This investment marks a key milestone in the company’s in... |
| - | eXmoor Pharma | “eXmoor – eXmoor pharma concepts limited” |